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Background. Estimates of drug resistance incidence to modern first-line combination antiretroviral therapies
against human immunodeficiency virus (HIV) type 1 are complicated by limited availability of genotypic drug
resistance tests (GRTs) and uncertain timing of resistance emergence.
Methods. Five first-line combinations were studied (all paired with lamivudine or emtricitabine): efavirenz
(EFV) plus zidovudine (AZT) (n5 524); EFV plus tenofovir (TDF) (n5 615); lopinavir (LPV) plus AZT (n5 573);
LPV plus TDF (n 5 301); and ritonavir-boosted atazanavir (ATZ/r) plus TDF (n 5 250). Virological treatment
outcomes were classified into 3 risk strata for emergence of resistance, based on whether undetectable HIV RNA
levels were maintained during therapy and, if not, whether viral loads were .500 copies/mL during treatment.
Probabilities for presence of resistance mutations were estimated from GRTs (n 5 2876) according to risk stratum
and therapy received at time of testing. On the basis of these data, events of resistance emergence were imputed for
each individual and were assessed using survival analysis. Imputation was repeated 100 times, and results were
summarized by median values (2.5th–97.5th percentile range).
Results. Six years after treatment initiation, EFV plus AZT showed the highest cumulative resistance incidence
(16%) of all regimens (,11%). Confounder-adjusted Cox regression confirmed that first-line EFV plus AZT
(reference) was associated with a higher median hazard for resistance emergence, compared with other treatments:
EFV plus TDF (hazard ratio [HR], 0.57; range, 0.42–0.76), LPV plus AZT (HR, 0.63; range, 0.45–0.89), LPV plus
TDF (HR, 0.55; range, 0.33–0.83), ATZ/r plus TDF (HR, 0.43; range, 0.17–0.83). Two-thirds of resistance events
were associated with detectable HIV RNA level #500 copies/mL during treatment, and only one-third with
virological failure (HIV RNA level, .500 copies/mL).
Conclusions. The inclusion of TDF instead of AZT and ATZ/r was correlated with lower rates of resistance
emergence, most likely because of improved tolerability and pharmacokinetics resulting from a once-daily dosage.
The combination of antiretroviral drugs against human
immunodeficiency virus type 1 (HIV-1) infection from
different classes has proven to be highly effective in
suppressing viral replication and has dramatically re-
duced HIV-1 infection–related morbidity and mortality
[1, 2]. Nevertheless, viral breakthrough caused by in-
complete drug intake and/or emergence of drug resistance
still poses a challenge for clinicians [3]. For example, in
the Swiss HIV Cohort Study (SHCS), we observed rates
of virological treatment failures with HIV RNA levels
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.500 copies/mL of 2.4 and 2.7 cases per 100 person-years
during therapy with nonnucleoside reverse-transcriptase in-
hibitor (NNRTI)–based and ritonavir-boosted protease in-
hibitor (PI/r)–based regimens, respectively, which often were
accompanied by the emergence of drug resistance mutations,
especially among NNRTI users [4].
Nevertheless, the proportion of individuals with HIV RNA
replication suppressed to ,50 copies/mL has increased con-
tinuously over the past decade [5, 6]. Whether the emergence of
HIV-1 drug resistance has been reduced by the same extent is
uncertain and difficult to assess [7, 8]. Incidence studies based
on genotypic drug resistance test (GRT) data from clinical
practice often struggle with limitations, namely, that patients
subjected to GRTs may not be representative for all potentially
eligible individuals or the whole population of HIV-infected,
treated individuals [3, 9]. Moreover, the actual event of re-
sistance emergence is usually not observable, and therefore, the
timing of the event is unclear.
Building on a previously published method to estimate the
prevalence of drug resistance among treated individuals [7], we
are presenting an imputation approach that can mitigate these
limitations. The general concept is as follows: On the basis of
HIV RNA level quantifications, we identify events during pa-
tients’ treatments that are associated with risk for drug resistance
emergence. Next, we try to quantify these risks by analyzing GRT
data, which were obtained under circumstances similar to the
risk event of interest in terms of ongoing or previous virological
failures and treatment received at time of drug resistance testing.
By using a simulation technique, we then explore the range of
possible incidence estimates under varying parameter estimates
for risks of resistance emergence.
METHODS
Patients and Data
Patients from the SHCS [10] were included who initiated
combination antiretroviral therapy (cART) from 1 January 1999
to 31 December 2010 with 1 of the 5 most frequently used
combinations [11]: efavirenz (EFV), zidovudine (AZT), and
lamivudine (3TC) (EFV1AZT group); lopinavir (LPV), AZT,
and 3TC (LPV1AZT group); EFV, tenofovir (TDF), and 3TC
or emtricitabine (FTC; EFV1TDF group); LPV, TDF, and 3TC
or FTC (LPV1TDF group); and ritonavir-boosted atazanavir
(ATZ/r), tenofovir (TDF), and 3TC or FTC (ATZ/r1TDF
group). The majority (.78%) of the 3 TDF-based regimens
contained FTC instead of 3TC. A minimum follow-up time of
180 days after treatment start was required for inclusion.
The SHCS is a multicenter, clinic-based cohort study that
includes 45% of all individuals who receive a diagnosis of HIV
infection in Switzerland, 70% of all patients receiving ART, and
75% of all patients with AIDS [10, 12]. The SHCS has been
approved by ethical committees of all participating institutions,
and written informed consent has been obtained from partic-
ipants. The collection of GRT data is described elsewhere [4, 13].
Definition of Risk States
Patients were classified into 3 risk states for the emergence of
drug resistance mutations, which were updated continuously
with each new viral load measurement. Situations in which in-
dividuals were either not receiving therapy or always had optimally
suppressed HIV viremia (ie, HIV RNA level,50 copies/mL) were
considered to be at low risk for resistance emergence; detectable
viremia (HIV RNA level #500 copies/mL) without subsequent
virologic suppression to HIV RNA level ,50 copies/mL during
the same therapy (to exclude blips in HIV RNA level [14, 15])
were classified as intermediate risks; and virological failures
with viral loads .500 copies/mL with the same regimen were
considered as high-risk events. For a given line of treatment,
patients could only move from a lower to a higher risk state but
not backward.
Estimation of Risk- and Treatment-Adjusted Probabilities of
Resistance
On the basis of a set of 2876 GRTs performed after $30 days of
continuous ART exposure and detailed treatment histories, we
calculated the probability for the detection of $1 International
AIDS Society (IAS)–USA drug resistance mutation [16]. These
analyses were stratified by the 3 aforementioned risk states and
treatments received at time of genotypic testing according to
6 categories: cART with boosted PI, unboosted PI, or NNRTI;
abacavir/3TC/AZT (Trizivir);#3 nucleoside reverse-transcriptase
inhibitors (NRTIs) (excluding Trizivir); and any other treat-
ment. Genotypic tests following virological failure events were
stratified further by whether they had been performed after the
first or later therapy failures. To limit the analysis to emerging
resistance during treatment, only mutations were evaluated
that corresponded to the treatment received at time of geno-
typic testing. Five groups of IAS-USA drug resistance muta-
tions were analyzed: thymidine analogue mutations (TAMs),
M184V and M184I, other NRTI mutations (eg, K65R and
L74V), major PI mutations, and NNRTI mutations.
Simulation
Given the risk state definitions and the associated probabilities
for detection of newly selected drug resistance mutations, we
scored each patient’s treatment history with respect to his or her
specific risk for the emergence of certain resistance mutation
groups. Using these individual risk assessments, we then gen-
erated new datasets, in which resistance emergence events were
imputed randomly around the time of transitions to higher risk
states (Figure 1). Next, incidence rates were calculated on the
basis of imputed risk events, and the range of possible incidence
estimates was explored by repeating the imputation procedure
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100 times, with newly sampled risks for resistance emergence
from distributions generated via bootstrapping.
Statistical Analysis
The main study outcomes were the emergence of any mutations
from the 5 groups and the emergence of triple-class drug re-
sistance, defined as the presence of $1 mutation from the
NNRTI and PI groups and$1 from any of the 3 groups of NRTI
mutations. Drug resistance mutations observed in the lowest
risk state (Supplementary Table 1; online only) were not con-
sidered as incident during therapy but as transmitted [17].
Each dataset of imputed resistance was analyzed by univariable
and multivariable Cox regression models to estimate the relative
hazard of drug resistance emergence across the 5 initial treatment
groups. Exposure time started at cART initiation (baseline) and
ended when the first simulated drug resistance mutation oc-
curred. Analyses were censored after 6 years of follow-up, and
comparisons were conducted on an intent-to-treat basis, which
means that patients who underwent switches in their first-line
regimens were also considered. Adjustments in the multivariable
model consisted of age, sex, ethnicity, risk group, and HIV RNA
level and CD4 cell count at treatment initiation. Unless stated
otherwise, point estimates are presented as the median and the
2.5th and 97.5th percentiles over all simulation runs (ie, the
range including 95% of all estimates). The simulation study was
performed using Stata SE software, version 11.2 (StataCorp).
RESULTS
Study Population
A total of 1139 patients receiving NNRTI and 1124 patients
receiving PI/r were included. Baseline characteristics, stratified
by cART received, are shown in Table 1. Individuals receiving
newer therapies based on EFV1TDF or ATZ/r tended to have
higher CD4 cell counts. Moreover, patients with higher pre-
treatment viral loads tended to receive PI/r-based regimens
Figure 1. Risk state classification and simulation of drug resistance for a hypothetical patient (example). For classification into risk states (upper panel),
longitudinal human immunodeficiency virus (HIV) RNA measurements and treatment histories were used to determine, at each HIV measurement, the risk state.
Low risks were defined as either being off therapy or always having had HIV RNA,50 copies. Note that blips (indicated by #1) were ignored. Intermediate risks
(#2) were defined as detectable viremia#500 copies without subsequent virologic suppression,50 copies on same therapy. High risks (#3) were defined as 2
consecutive HIV RNA.500 copies or 1 HIV RNA.500 copies and stop or modification of therapy (virological failure). The simulation of resistance was done as
follows: at transitions to higher-risk states (indicated by #2 and #3, upper panel), a random number between 0 and 1 was drawn. If this number exceeded the risk
for resistance as estimated from genotypic resistance tests (middle panel, data shown in Supplementary Table 1; online only), resistance mutations,
corresponding to current antiretroviral therapy exposure, were assumed to have emerged (lower panel). Timing of emergence (indicated by arrows, upper panel)
was randomly placed between the risk event (ie, the transition to a higher risk category, labels #2 and #3, upper panel) and preceding HIV RNA. For example, if
this patient who previously had an intermediate risk event on an unboosted protease inhibitor therapy experienced the first virological failure on a combination
treatment including nonnucleoside reverse-transcriptase inhibitors, this individual had a 70.2% chance to have at least 1 resistance mutation detected by
genotypic testing (Supplementary Table 1; online only). To simulate resistance emergence in this individual, a decision was made whether the mutation has
occurred with a 70.2% probability, and if so, when the event took place, which was sometime between the last undetectable viral load and the first viral
load.500 copies/mL. These decisions were governed by draws of uniformly distributed random numbers ranging from 0 to 1; if this number was less or equal
to the current risk for mutations (here 0.702), then mutations were assumed to be present. Similarly, a random number determined the fraction of the absolute
time distance between the last undetectable and the first viral load.500 copies at which the event took place. These procedures were repeated 100 times to
generate 100 datasets, in which resistance emergence events were assigned randomly, but taking into account patients' risk profiles.
Abbreviations: 3TC, lamivudine; AZT, zidovudine; EFV, efavirenz; FTC, emtricitabine; LPV, lopinavir; Mut, type of mutations; NFV, nelfinavir; NNRTI, nonnucleoside
reverse-transcriptase inhibitor; Prob. Res., probability for resistance emergence; TDF, tenofovir.
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more frequently, as indicated by the higher 75th percentiles of
baseline HIV RNA level in the 2 types of lopinavir-based
treatments, compared with the other groups, reflecting recom-
mendations by earlier guidelines [18, 19].
Characteristics of the study population at the last follow-up
visit or at year 6 after therapy start, whichever occurred first, are
shown in Table 2. Over a mean follow-up time of 4.5 years, 325
individuals (14.4%) experienced intermediate risk events for
drug resistance emergence (ie, low-level viremia while receiving
cART), and 109 (4.8%) had virologically failed at least 1 therapy.
Table 2 indicates that being female, being of black ethnicity,
having acquired HIV infection through heterosexual contact,
and having a baseline CD4 cell count #200 cells/lL were asso-
ciated with virological failure. Among all individuals who ex-
perienced an intermediate risk event or a virological failure, 21%
and 64%, respectively, also had GRTs performed (Supplemen-
tary Table 2; online only). No major testing biases were detected
apart from the finding that more recent risk events were less
likely to have corresponding genotypic data available. This is
attributable to 2 factors: first, there is a certain delay in trans-
ferring GRT data to the SHCS, and second, treatment switches
owing to suspected treatment failure have often occurred at
plasma viral loads #500 copies/mL in more recent years, which
affects chances for successful viral genotyping [20].
Rates of Resistance Emergence
Intent-to-treat rates of mutation emergence from the simulation
are shown in Table 3. The EFV1AZT group exhibited the
highest rates, with 2.6 events per 100 person-years of treatment
exposure, whereas the 4 other groups showed rates between
1.45 (ATZ/r1TDF) and 1.92 (EFV1TDF) events per 100
person-years. This higher rate of mutation emergence among
EFV1AZT recipients was partially driven by the frequent de-
tection of the 3TC mutation M184V, which occurred more
than twice as often as in any other treatment group. This ob-
servation also explained the marked difference in overall mu-
tation rates between EFV1AZT and the second NNRTI group
(EFV1TDF), whereas rates of NNRTI mutations were com-
parable between the 2 NNRTI groups.
Analyses of the origins of mutations in terms of risk
stratum showed that, across all treatment groups, almost
two-thirds of mutations (median over 100 simulations, 65%)
emerged while individuals had experienced detectable viral
loads #500 copies /mL during therapy. This proportion was
lowest in the EFV1AZT group (52%) and highest in the
LPV1TDF group (83%; also LPV1AZT: 73%; EFV1TDF:
69%; ATZ/r1TDF: 75%).
Time-to-Event Analyses of Resistance Emergence
When analyzing resistance emergence with the Kaplan-Meier
method (Figure 2), the median intent-to-treat cumulative in-
cidence of drug resistance mutations after 6 years of follow-up
was highest in the EFV1AZT group (16% [2.5th–97.5th per-
centile, 14%–18%]), compared with other types of initial
treatments (EFV1TDF: 9% [7%–11%]; LPV1AZT: 10%
[8%–12%]; LPV1TDF: 7% [5%–11%]). Because of limited
Table 1. Baseline Characteristics of Treatment Groups
Variable EFV/AZT/3TC
EFV/TDF/FTC
or 3TC LPV/AZT/3TC
ATV/RTV/TDF/FTC
or 3TC
LPV/TDF/FTC
or 3TC P value
No. of patients 524 615 573 250 301
Mode of HIV acquisition ,.001
Heterosexual contacts 280 (53.4%) 258 (42.0%) 281 (49.0%) 86 (34.4%) 127 (42.2%)
Intravenous drug use 64 (12.2%) 38 (6.2%) 65 (11.3%) 35 (14.0%) 32 (10.6%)
Homosexual contacts 180 (34.4%) 319 (51.9%) 227 (39.6%) 129 (51.6%) 142 (47.2%)
Female sex 166 (31.7%) 120 (19.5%) 197 (34.4%) 53 (21.2%) 77 (25.6%) ,.001
Median age at baseline (IQR) 38 (32–44) 40 (33–46) 36 (30–44) 40 (34–46) 40 (34–46) ,.001
Ethnicity .326
White 393 (75.0%) 464 (75.4%) 421 (73.5%) 206 (82.4%) 224 (74.4%)
Black 85 (16.2%) 91 (14.8%) 99 (17.3%) 26 (10.4%) 48 (15.9%)
Unknown/Other 46 (8.8%) 60 (9.8%) 53 (9.2%) 18 (7.2%) 29 (9.6%)
Median baseline CD4 cell
count (IQR)
196 (110–288) 242 (154–317) 219 (110–357) 244 (160–323) 209 (92–303) ,.001
Median baseline log10 HIV
RNA level (IQR)
5 (4.5–5.5) 4.7 (4.3–5.2) 5.1 (4.6–5.7) 4.9 (4.4–5.2) 5 (4.4–5.5) ,.001
Median year of ART
initiation (IQR)
2002 (2001–2004) 2007 (2006–2008) 2005 (2003–2007) 2008 (2006–2009) 2007 (2006–2008) ,.001
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; ATV, atazanavir; AZT, zidovudine; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency
virus; IQR, interquartile range; LPV, lopinavir; RTV, ritonavir-boosted; TDF, tenofovir.
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follow-up, only a 4-year cumulative incidence could be esti-
mated with adequate precision for the ATZ/r1TDF group
(5% [2%–8%]), which was lower than the smallest 4-year risk
among the other 4 groups (LPV1TDF: 7% [5%–10%]). Of
note, all these estimates were higher than estimates based on
measured drug resistance or virological failure events (Figure 2).
For instance, in the EFV1AZT group, measured drug re-
sistance (7%) or virological failure (10%) 6 years after therapy
initiation was considerably less frequent than simulated re-
sistance (16%).
Next, simulated resistance emergence was analyzed with re-
gression models. The median hazard ratios (2.5th–97.5th per-
centile) from unadjusted Cox regressions using EFV1AZT
as reference were as follows: EFV1TDF: 0.53 (0.41–0.68);
LPV1AZT: 0.62 (0.49–0.80); LPV1TDF: 0.50 (0.31–0.73); and
ATV1TDF: 0.40 (0.18–0.67). These point estimates varied little
when adjusted Cox regression analyses were performed (Table 4)
and provided strong evidence for the inferiority of EFV/AZT/
3TC with regard to drug resistance emergence relative to all
other groups. Furthermore, having a high HIV RNA load
Table 2. Characteristics of Study Population 6 Years After Therapy Initiation or Time of Last Follow-up (Whichever Occurred First)
Characteristic
Always optimally
treated (n 5 1829)
Ever low-level viremia
while on ART (n 5 325)
Ever virological treatment
failure (n 5 109)
Type of initial combination therapy
NNRTI
Efavirenz/zidovudine/lamivudine or emtricitabine 403 (22.0%) 74 (22.8%) 47 (43.1%)
Efavirenz/tenofovir/lamivudine or emtricitabine 539 (29.5%) 58 (17.8%) 18 (16.5%)
Boosted PI
Lopinavir/zidovudine/lamivudine or emtricitabine 446 (24.4%) 100 (30.8%) 27 (24.8%)
Boosted atazanavir/tenofovir/lamivudine or emtricitabine 199 (10.9%) 42 (12.9%) 9 (8.3%)
Lopinavir/tenofovir/lamivudine or emtricitabine 242 (13.2%) 51 (15.7%) 8 (7.3%)
Characteristics by risk states
Female sex 482 (26.4%) 91 (28.0%) 40 (36.7%)
Median age (IQR) 39 (32–45) 38 (31–46) 35 (30–42)
Ethnicity
White 1398 (76.4%) 241 (74.2%) 69 (63.3%)
Black 258 (14.1%) 60 (18.5%) 31 (28.4%)
Unknown/Other 173 (9.5%) 24 (7.4%) 9 (8.3%)
Mode of HIV acquisition
Heterosexual contacts 806 (44.1%) 161 (49.5%) 65 (59.6%)
Intravenous drug use 179 (9.8%) 40 (12.3%) 15 (13.8%)
Homosexual contacts 844 (46.1%) 124 (38.2%) 29 (26.6%)
Median baseline CD4 cells/lL (IQR) 228 (138–321) 204 (105–303) 166 (48–263)
Baseline CD4 #200 cells/lL 761 (41.6%) 158 (48.6%) 64 (58.7%)
Median baseline log10 HIV RNA (IQR) 4.9 (4.4–5.3) 5.2 (4.8–5.6) 5.0 (4.6–5.7)
Baseline HIV RNA $5 log10 copies/mL 773 (42.3%) 200 (61.5%) 56 (51.4%)
Median year of ART initiation (IQR) 2006 (2004–2008) 2006 (2003–2008) 2004 (2002–2006)
Ever had a GRT in current state 140 (7.7%) 67 (20.6%) 69 (63.3%)
Of those with GRT, ever resistance detected 11 (7.9%) 28 (41.8%) 46 (66.7%)
Treatment at last follow-up before or at year 6
2 or 3 NRTIs 1 1 boosted PI 747 (40.8%) 174 (53.5%) 55 (50.5%)
2 or 3 NRTIs 1 1 NNRTI 922 (50.4%) 95 (29.2%) 25 (22.9%)
2 or 3 NRTIs 1 1 unboosted PI 26 (1.4%) 8 (2.5%) 4 (3.7%)
Trizivir (zidovudine/lamivudine/abacavir) 85 (4.6%) 11 (3.4%) 2 (1.8%)
#3 NRTIs (excl. Trizivir) 24 (1.3%) 21 (6.5%) 7 (6.4%)
Other combinations (eg, NNRTI1PI, mono PI) 25 (1.4%) 16 (4.9%) 16 (14.7%)
Median follow-up time in years (IQR) 3.9 (2.0–5.3) 3.8 (1.8–5.2) 4.9 (3.5–5.5)
Died before year 6 36 (2.0%) 16 (4.9%) 4 (3.7%)
Lost to follow-up before year 6 176 (9.6%) 50 (15.4%) 31 (28.4%)
Abbreviations: ART, antiretroviral therapy; GRT, genotypic drug resistance test; HIV, human immunodeficiency virus; IQR, interquartile range; NNRTI,
nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
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$100 000 copies/mL at time of therapy start and black eth-
nicity showed strong associations with more frequent drug
resistance emergence. Results changed little in predefined
subanalyses, in which the Cox model estimation was restricted
to individuals with baseline viral loads $100 000 copies/mL
(n5 1029) or to modern TDF-containing treatments (n5 1166).
In this latter analysis, none of the 3 TDF-based treatments showed
significantly different rates of resistance emergence, although
treatments with ATZ/r maintained the lowest hazard ratio (0.73
[0.37–1.31]), compared with LPV (0.91 [0.58–1.34]) or EFV
(reference).
Comparison of Simulation Results With Standard Data Analyses
Finally, we aimed to compare the simulation results with those
obtained from standard time to event analyses, with virological
failure or detection of resistance as end points (Table 4). In
general, the point estimates from the simulation study seemed to
be compatible with the findings from standard analyses. Al-
though in some cases not statistically significant, all 4 drug
combinations showed hazard ratios of about the same magni-
tude as in the simulation study. In addition, black ethnicity
emerged as a risk factor in all 3 analyses. Discrepancies were
observed with respect to low CD4 cell counts #200 cells/lL at
baseline, which was significantly associated with the detection of
resistance mutations in the virologic failure study but not in the
other analyses (possibly reflecting a testing bias; Supplementary
Table 2; online only). In addition, although hazard ratios of
baseline HIV RNA level $100 000 copies/mL indicated associ-
ations with higher outcome rates in all 3 analyses, statistical
significance was only reached in the simulation study.
DISCUSSION
By applying a novel imputation method for estimation of drug
resistance emergence, we observed surprisingly robust patterns
across the 5 groups of cART under consideration. Over a mean
observation period of 4.5 years, rates of emergence of any re-
sistance ranged from 1.5 to 2.6 events per 100 person-years
during treatment. The majority of events were related to
emergence of 3TC or FTC resistance (ie, M184V; 33%–78% of
mutations; Table 3) and, in individuals starting NNRTI-based
Table 3. Simulated Numbers and Rates of Occurrence of Specific Mutations Over 100 Simulation Runsa
EFV/AZT/3TC
(n 5 524)
EFV/TDF/FTC or
3TC (n 5 615)
LPV/AZT/3TC
(n 5 573)
LPV/TDF/FTC or
3TC (n 5 301)
ATV/RTV/TDF/FTC or
3TC (n 5 250)
Person-years of follow-up 3274 1722 2592 883 622
Any IAS-USA mutations
Number of events 85 (81–88) 33 (30–36) 49 (46–52) 17 (15–18) 9 (8–11)
Rate per 100 person-years 2.60 (2.23–2.96) 1.92 (1.48–2.41) 1.90 (1.49–2.38) 1.91 (1.22–2.55) 1.45 (0.79–2.30)
M184V/I
Number of events 66 (62–69) 13 (11–15) 32 (28–35) 9 (7–10) 3 (2–4)
Rate per 100 person-years 1.97 (1.63–2.34) 0.74 (0.51–1.03) 1.21 (0.86–1.61) 0.99 (0.44–1.35) 0.47 (0–0.96)
Thymidine analogue mutations
Number of events 25 (23–28) 3 (2–4) 6 (5–8) 3 (2–4) 0 (0–0)
Rate per 100 person-years 0.71 (0.50–0.96) 0.17 (0.02–0.28 ) 0.22 (0.11–0.37) 0.32 (0–0.55) 0 (0–0)
Other NRTI mutations
Number of events 9 (8–11) 12 (9–15) 11 (9–13) 3 (2–4) 2 (1–3)
Rate per 100 person-years 0.25 (0.11–0.45) 0.68 (0.28–1.13) 0.40 (0.18–0.63) 0.33 (0–0.77) 0.31 (0–0.80)
NNRTI mutations
Number of events 58 (55–62) 26 (24–28) 28 (25–30) 6 (5–8) 3 (3–4)
Rate per 100 person-years 1.71 (1.40–2.03) 1.49 (1.08–1.86) 1.05 (0.76–1.34) 0.66 (0.33–1) 0.48 (0.16–0.96)
PI mutations
Number of events 21 (19–24) 6 (4–7) 17 (14–19) 8 (6–9) 5 (4–6)
Rate per 100 person-years 0.59 (0.39–0.82) 0.34 (0.11–0.56) 0.63 (0.34–0.94) 0.88 (0.43–1.56) 0.79 (0.16–1.46)
Mutations against 3 classes
Number of events 11 (10–13) 3 (2–4) 6 (4–7) 1 (1–2) 0 (0–1)
Rate per 100 person-years 0.31 (0.17–0.48) 0.17 (0–0.34) 0.22 (0.07–0.37) 0.11 (0–0.33) 0 (0–0.32)
Abbreviations: 3TC, lamivudine; ATV, atazanavir; AZT, zidovudine; EFV, efavirenz; FTC, emtricitabine; IAS-USA, International AIDS Society–USA; LPV, lopinavir;
NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; RTV, ritonavir-boosted; TDF, tenofovir.
a Analyses were performed on an intent-to-treat basis, meaning that resistance emergence events occurring on later lines of regimens were still attributed to the
respective group of first-line therapy. Data are presented as median (IQR) for number of events or median (2.5th-97.5th percentiles) for rates.
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regimens, to NNRTI resistance mutations (68% and 79% of
mutations in the EFV1AZT and EFV1TDF groups, re-
spectively). In contrast, resistance to PIs among first-line PI
users contributed less to overall resistance (35%–56%), which
has been shown previously by observational data [4] and ran-
domized clinical trials [21, 22]. In line with previous findings of
improved response rates to ART over time [5, 6], resistance
emergence seemed to have become rarer with novel treatment
combinations. When compared with the simulation results from
an outdated unboosted PI combination (NFV/AZT/3TC, with
5.5 [4.6–6.4] resistance emergence events per 100 person-years;
data not shown), all 5 groups had markedly lower resistance
rates. Moreover, newer TDF-based NNRTI treatments showed
smaller rates of resistance (1.9 events per 100 person-years of
treatment; Table 3) than did older AZT-based NNRTI treat-
ments (2.6 events per 100 person-years). Similarly, newer
treatments based on ATZ/r and TDF showed trends for lower
rates of resistance emergence (1.5 events per 100 person-years)
than did LPV+AZT (1.9 events per 100 person-years) or
LPV1TDF (1.9 events per 100 person-years). After adjustment
for potential confounders, the EFV1AZT group was the com-
bination with the highest resistance rate, whereas the other 4
combinations seemed to be equivalent. These observations are in
line with a recent survey on the durability of different first-line
regimens in Switzerland that identified AZT/3TC-based NRTI
backbones as a risk factor for toxicity-related treatment mod-
ifications [11]. The generally more favorable risk profile of TDF-
based treatments for the emergence of drug resistance may
therefore be mediated by better tolerability, less toxicity, and
more favorable pharmacokinetics [23]. Overall, ATZ/r regimens
showed the lowest rates for emergence of resistance. Although an
influence of the somewhat shorter follow-up time in this group
cannot be fully excluded—which would be relevant if resistance
rates were increasing with prolonged treatment duration—ATZ/r
treatments have also proven, in routine clinical care [11] and in
randomized clinical trials [24], to be durable and well tolerated,
thereby promoting adherence and, possibly, reducing the risk
for the emergence of resistance. Another remarkable finding
was the high proportion of resistance emerging from inter-
mediate risk events (ie, HIV RNA level #500 copies/mL),
which argues for close monitoring of antiretroviral therapy
and immediate treatment switches even at relatively low HIV
RNA levels if virological failure is suspected. It is likely that
many of these intermediate-risk situations would develop
into full virological failure, and early intervention, as is stan-
dard in Switzerland, can be a strategy to limit resistance and
to preserve future treatment options.
Because of methodological challenges, few studies have at-
tempted to assess the incidence of drug resistance with NNRTI
or boosted PI therapy, and results are difficult to compare [9, 22,
25, 26]. The most similar study to ours was performed by the UK
Collaborative Group on HIV Drug Resistance [9] and involved
an assessment of 7891 individuals starting either NNRTI-based
(83%) or PI/r-based (17%) combination treatments. Of those,
Figure 2. Kaplan-Meier curves for virological failure events (dark grey solid line), detection of drug resistance mutations (light grey solid line) as
observed in data, or simulated emergence of drug resistance on the basis of patient-specific risk profiles (dashed line). Abbreviations: 3TC, lamivudine;
ATV/r, ritonavir-boosted atazanavir; AZT, zidovudine; EFV, efavirenz; FTC, emtricitabine; LPV, lopinavir; TDF, tenofovir.
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1359 patients (17%) experienced virological failure; however, as
a limitation, only 48% had been genotyped for drug resistance
mutations. The authors reported cumulative incidences of
14.9% (NNRTI) and 14.7% (PI/r) for detection of any drug
resistance 6 years after treatment initiation. In contrast, the
6-year cumulative incidence estimates from this study were
12.9% for the pooled NNRTI group and 9.0% for the pooled
PI/r group. It should be noted, however, that the majority of
resistance in our simulation emerged from intermediate-risk
events, which were not considered in the UK study. Moreover,
the failure rates observed in our study differed markedly from
the one reported by the UK group (5% vs 25%), possibly be-
cause of the higher proportion of individuals starting therapy
with more modern drugs, such as TDF or ATZ/r.
A second study analyzed drug resistance emergence among
individuals newly starting NNRTI- or PI/r-based combination
therapy in Denmark [25]. The authors recorded 247 viro-
logical failures among 1829 ART initiators, of whom 23% had
genotypic data available (compared with 65% in our study).
With 0.6 events per 100 person-years, their incidence estimate
was much lower than our rates (range, 1.5–2.6 events per 100
person-years) (Table 3). Because the focus of the Danish study
was on time trends, they chose a very conservative study
design, thereby accepting an underestimation of actual event
rates.
The validity of our incidence estimates relies on assump-
tions. The accuracy of the simulation is dependent on the
quality of the dataset, such as the frequency and completeness
of HIV RNA measurements and treatment information. In
addition, it is important that the risk state–specific estimates
for the presence of resistance mutations are not affected unduly
by testing biases. This latter assumption can safely be consid-
ered to be fulfilled for the high and intermediate risk states
(Supplementary Table 2; online only). However, this is not the
case for estimates derived from genotypic tests performed while
an individual was still at low risk for the emergence of re-
sistance. The estimate for any resistance mutations in this
stratum was around approximately 16% and was mostly driven
by NNRTI resistance (Supplementary Table 1; online only),
thus considerably above levels of transmitted resistance in
Switzerland [17]. An inspection of treatments and longitudinal
CD4 cell count and viral load measurements revealed that these
genotypic tests were often performed in situations in which
a patient’s treatment history was uncertain or after single or
repeated low-level viremia with subsequent suppression to un-
detectable HIV RNA levels during the same treatment (this latter
Table 4. Comparison of Results From the Simulation Analysis and Conventional Data Analyses Using Virological Failures >500 Copies/mL
HIV RNA or Detection of any Drug Resistance by Genotypic Resistance Testing as Endpointsa
Simulated IAS-USA mutations Detected IAS-USA mutations Virological Failures
Number of events 253 (median) 85 109
Female sex 1.06 (0.81–1.36) 0.86 (0.51–1.44) 0.90 (0.57–1.40)
Age (per additional year) 0.94 (0.85–1.07) 0.98 (0.96–1.00) 0.97 (0.95–1.00)
Ethnicity
White Reference Reference Reference
Black 1.58 (1.11–2.09) 2.78 (1.55–4.98) 1.88 (1.12–3.17)
Unknown/Other 0.89 (0.52–1.33) 0.79 (0.33–1.89) 0.92 (0.45–1.91)
Mode of HIV acquisition
Heterosexual contact Reference Reference Reference
Intravenous drug use 1.16 (0.81–1.65) 1.11 (0.51–2.42) 1.27 (0.70–2.30)
Homosexual contact 0.75 (0.56–1.01) 1.32 (0.76–2.32) 0.66 (0.39–1.11)
Baseline CD4 #200 cells/lL 1.14 (0.93–1.44) 1.39 (0.94–2.04) 1.70 (1.12–2.59)
Baseline HIV RNA $5 log10 copies/mL 1.49 (1.19–1.81) 1.12 (0.76–1.64) 1.45 (0.95–2.19)
Type of initial combination therapy
EFV/AZT/3TC Reference Reference Reference
EFV/TDF/FTC or 3TC 0.57 (0.42–0.76) 0.69 (0.40–1.18) 0.54 (0.31–0.94)
ATV/TDF/FTC or 3TC 0.43 (0.17–0.83) 0.47 (0.18–1.20) 0.81 (0.39–1.68)
LPV/AZT/3TC 0.63 (0.45–0.89) 0.51 (0.30–0.87) 0.57 (0.36–0.91)
LPV/TDF/FTC or 3TC 0.55 (0.33–0.83) 0.55 (0.26–1.14) 0.46 (0.21–0.97)
Numbers printed in bold are statistically significant, because their simulation intervals or the confidence intervals do not contain the value 1.
Abbreviations: 3TC, lamivudine; ATV, atazanavir; AZT, zidovudine; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus; IAS-USA, International
AIDS Society–USA; LPV, lopinavir; RTV, ritonavir-boosted; TDF, tenofovir.
a Data are presented as median hazard ratios (2.5th and 97.5th percentiles) over 100 simulation runs (column 1) or point estimates and likelihood-ratio confidence
intervals from standard Cox proportional hazard regressions (columns 2 and 3).
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criterion was responsible for the classification into the low-risk
stratum). Although these observations are suggestive for the
emergence of resistance mutations in the presence of low-level
viremia, we chose to ignore these risk estimates from the lowest
risk stratum for the simulation, because it was not possible to
identify such elevated risks specifically. Moreover, a simulation
of resistance in the low-risk strata on the basis of the observed
resistance probabilities (Supplementary Table 1; online only)
would lead to highly exaggerated incidence rates.
To conclude, this newly developed simulation approach
complements recent methodological advances in estimating
drug resistance prevalence among ART-exposed individuals.
The concept can readily be implemented to any observational
setting with treatment and laboratory data collections and cor-
responding genotypic data available. Despite the large variability
of parameter estimates, the incidence estimates were surprisingly
robust, and they document the continuous progress in HIV
treatment, marked by reductions in the emergence of resistance
and increased proportions of treated individuals with continu-
ously undetectable HIV RNA levels.
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Supplementary materials are available at Clinical Infectious Diseases
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tents of all supplementary data are the sole responsibility of the authors.
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